Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.

STOCKHOLM, Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were ...

The study randomized 1795 patients in a 1:1 ratio to receive either intravenous Leqembi or placebo. The primary end point was the change from baseline at 18 months in the score on the Clinical ...

The company also raised its full-year profit guidance. Sales of its breakthrough Alzheimer's drug, Leqembi, along with new rare disease and depression treatments, helped offset a year-over-year ...